DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-5.4%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.04B
AUM Growth
+$5.04B
(-4%)
Cap. Flow
+$166M
Cap. Flow
% of AUM
3.28%
Top 10 Holdings %
Top 10 Hldgs %
52.76%
Holding
153
New
45
Increased
20
Reduced
17
Closed
29
Top Buys
| 1 |
United Therapeutics
UTHR
|
$84.8M |
| 2 |
Pfizer
PFE
|
$84.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$69.3M |
| 4 |
Insmed
INSM
|
$34.9M |
| 5 |
Vera Therapeutics
VERA
|
$25.2M |
Top Sells
| 1 |
WAY
Waystar Holding Corp
WAY
|
$121M |
| 2 |
Owens & Minor
OMI
|
$64.2M |
| 3 |
Alignment Healthcare
ALHC
|
$51M |
| 4 |
Galapagos
GLPG
|
$38.8M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$31.3M |
Sector Composition
| 1 | Healthcare | 87.58% |
| 2 | Real Estate | 0.01% |
| 3 | Technology | 0.01% |
| 4 | Consumer Discretionary | 0.01% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $1.28B | 25.19% | 17,991,024 | – | – |
|
2
Viatris
VTRS
$12.3B
| $209M | 4.13% | 23,991,594 -4,442 | -0% | -$38.7K |
|
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $165M | 3.25% | 1,489,000 +627,000 | +73% | +$69.3M |
|
4
Centene
CNC
$14.3B
| $162M | 3.2% | 2,671,921 | – | – |
|
5
Oscar Health
OSCR
$4.31B
| $155M | 3.07% | 11,840,818 +5,818 | +0% | +$76.3K |
|
6
Merus
MRUS
$4.98B
| $134M | 2.64% | 3,173,928 +201,141 | +7% | +$8.47M |
|
7
ARS Pharmaceuticals
SPRY
$1.15B
| $132M | 2.61% | 10,514,657 | – | – |
|
8
Revolution Medicines
RVMD
$7.1B
| $117M | 2.32% | 3,317,332 +59,000 | +2% | +$2.09M |
|
9
AdaptHealth
AHCO
$1.28B
| $105M | 2.08% | 9,711,410 | – | – |
|
10
Indivior
INDV
$3.03B
| $101M | 1.99% | 10,567,160 +1,684,000 | +19% | +$16M |
|
11
Brookdale Senior Living
BKD
$1.83B
| $97.7M | 1.93% | 15,612,264 | – | – |
|
|
12
Alignment Healthcare
ALHC
$3.24B
| $85M | 1.68% | 4,567,473 -2,736,829 | -37% | -$51M |
|
|
13
United Therapeutics
UTHR
$13.8B
| $84.8M | 1.68% | +275,226 | New | +$84.8M |
|
|
14
Pfizer
PFE
$141B
| $84.8M | 1.67% | +3,347,296 | New | +$84.8M |
|
15
NewAmsterdam Pharma
NAMS
$2.71B
| $84M | 1.66% | 4,103,957 -210,383 | -5% | -$4.31M |
|
16
Catalyst Pharmaceutical
CPRX
$2.52B
| $83M | 1.64% | 3,422,149 +289,138 | +9% | +$7.01M |
|
17
Dynavax Technologies
DVAX
$1.19B
| $67.3M | 1.33% | 5,191,493 -2,330 | -0% | -$30.2K |
|
18
Baxter International
BAX
$12.7B
| $65.8M | 1.3% | 1,923,100 | – | – |
|
19
Legend Biotech
LEGN
$6.41B
| $59.2M | 1.17% | 1,743,555 +191,837 | +12% | +$6.51M |
|
20
Bio-Rad Laboratories Class A
BIO
$8.06B
| $55.1M | 1.09% | 226,070 +74,426 | +49% | +$18.1M |
|
21
IDEAYA Biosciences
IDYA
$2.15B
| $53.5M | 1.06% | 3,267,551 +531,551 | +19% | +$8.71M |
|
22
Edgewise Therapeutics
EWTX
$1.51B
| $45.7M | 0.9% | 2,078,509 | – | – |
|
23
Larimar Therapeutics
LRMR
$310M
| $45.6M | 0.9% | 21,231,974 | – | – |
|
24
Enhabit
EHAB
$399M
| $43.9M | 0.87% | 4,997,746 -13,226 | -0.3% | -$116K |
|
25
Alnylam Pharmaceuticals
ALNY
$58.5B
| $39.2M | 0.77% | 145,000 -191 | -0.1% | -$51.6K |
|